Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shilpa Bhatnagar

Internal Medicine Tempe, AZ Medical Doctor

NPI 1851385876 CMS profile 128919

2153 E Baseline Rd, Suite 101, Tempe, AZ 85283

Open in the dashboard

General payments

$6,349

336 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shilpa Bhatnagar of Tempe, AZ is reported in the CMS Open Payments database as having received $6,349 across 336 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,324 66
2024 General $1,165 56
2023 General $1,095 61
2022 General $1,001 58
2021 General $776 39
2020 General $101 7
2019 General $886 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shilpa Bhatnagar
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Shilpa Bhatnagar were reported at $1,324. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Shilpa Bhatnagar Internal Medicine median Middle half National median
2019 $886 $159 $48–$570 $163
2020 $101 $119 $33–$402 $114
2021 $776 $135 $37–$521 $132
2022 $1,001 $141 $42–$496 $149
2023 $1,095 $149 $45–$519 $160
2024 $1,165 $154 $47–$537 $164
2025 $1,324 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $538 35 payments
  2. AbbVie, Inc. $484 31 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $477 25 payments
  4. AstraZeneca Pharmaceuticals LP $472 22 payments
  5. Lilly USA, LLC $442 27 payments
  6. GlaxoSmithKline, LLC. $371 19 payments
  7. Amgen Inc. $292 11 payments
  8. Dexcom, Inc. $258 11 payments
  9. Pfizer Inc. $250 15 payments
  10. Philips Electronics North America Corporation $206 12 payments
  11. Other $2,558 128 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,295 332 payments
  2. Education $38 3 payments
  3. Entertainment $16 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $398 25 payments
  2. RYBELSUS $350 21 payments
  3. GEMTESA $319 18 payments
  4. TRELEGY ELLIPTA $298 14 payments
  5. MOUNJARO $272 16 payments
  6. FARXIGA $258 14 payments
  7. Dexcom G6 Transmitter $245 10 payments
  8. Prolia $236 7 payments
  9. UBRELVY $224 14 payments
  10. ZAVZPRET $205 12 payments
  11. Other $4,831 256 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 132 drugs

Part D claims

8,149

Median for Internal Medicine: 777

Drug cost

$1,042,272

Median for Internal Medicine: $73,373

Branded share of claims

19.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 139 $217,980
Mounjaro Tirzepatide Brand 73 $116,565
Gemtesa Vibegron Brand 45 $56,900
Rybelsus Semaglutide Brand 19 $46,025
Jardiance Empagliflozin Brand 26 $42,897
Eliquis Apixaban Brand 32 $42,794
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 41 $39,979
Linzess Linaclotide Brand 38 $37,724
Trulicity Dulaglutide Brand 26 $37,009
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 39 $36,610

The 10 drugs with the highest cost, of 132 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$87,281

Of which drugs: $1,558

Medicare patients

195

Average age 74

Services billed

1,278

138 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 38%
Depression 30%
Diabetes 25%
Osteoporosis 22%
Ischemic heart disease 21%
Chronic kidney disease 21%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 42 42 $1,517

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $91
$91 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $56
  • Lilly USA, LLC $18
$74 26 —
GEMTESA
  • Sumitomo Pharma America, Inc. $74
$74 45 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $60
$60 12 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $54
$54 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

336 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record